Volume 24, Number 7—July 2018
Perspective
Progress in Vaccine-Preventable and Respiratory Infectious Diseases—First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006–2015
Table 2
New vaccine (indication) | Date of ACIP recommendation |
---|---|
Meningococcal ACWY conjugate (adolescents) | 2005 Feb |
Tdap (adolescents) | 2005 Jun |
Measles, mumps, rubella, and varicella (MMRV) | 2005 Oct |
Influenza (24–59-month-old children) | 2006 Feb |
Rotavirus (infants) | 2006 Feb |
Human papillomavirus (adolescent girls) | 2006 Jun |
Second-dose varicella | 2006 Jun |
Zoster (shingles) | 2006 Oct |
Influenza (persons 6 mo–18 y of age) | 2009 Feb |
13-valent pneumococcal conjugate vaccine (children) | 2010 Feb |
Influenza (universal in persons >6 mo of age) | 2010 Feb |
Second dose of meningococcal ACWY conjugate (adolescents) | 2010 Oct |
Human papillomavirus (adolescent boys) | 2011 Oct |
Tdap (in every pregnant woman) | 2012 Oct |
13-valent pneumococcal conjugate vaccine (persons >65 years of age) | 2014 Aug |
Meningococcal B vaccine (during outbreaks and in high-risk persons) | 2015 Feb |
HPV-9 (adolescents) | 2015 Feb |
Meningococcal B (adolescents, category B) | 2015 Jun |
*ACIP, Advisory Committee on Immunization Practices; HPV, human papillomavirus; Tdap, tetanus, diphtheria, and acellular pertussis.
1Current affiliation: Emory University, Atlanta, Georgia, USA.
2Current affiliation: World Health Organization, Cairo, Egypt.
Page created: June 18, 2018
Page updated: June 18, 2018
Page reviewed: June 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.